Viking's pipeline may release its value next year, and larger companies are likely to consider acquiring it.Upstart biotech company Viking Therapeutics (VKTX 1.27%) is a potential takeover candidate in 2026. That's not a reason to buy the stock in itself, but does highlight the potential value in its product pipeline. Here's why major drugmakers might now be drawn to buying this relatively small player in the pharmaceutical industry.Takeover activity is high in the industryThe recent bidding war between Pfi ...

Fizer falling after announcing its 2026 guidance. Our Anakica Kim Constantino has some details as the market didn't appreciate much what we got for the new year. Anakah, >> that's right, Carl.So, Fiser today issuing a modest 2026 guidance saying it expects sales to come in between 59.5% billion to 62.5% billion. And that's roughly in line with the street, but largely flat compared to the 62 billion in sales that expects for 2025. And in terms of its profit guidance, it came in slightly below what the street ...

Donovan Jones is an IPO research specialist with 15 years of experience identifying opportunities for high quality IPOs.He also leads the investing group IPO Edge, which offers actionable information on growth stocks through first-look IPO filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates. Learn moreAnaly ...

By STAN CHOE, AP Business WriterNEW YORK (AP) — The U.S. stock market is slipping on Tuesday following mixed data on the economy’s strength, which did little to clear uncertainty about where interest rates may be heading. The S&P 500 fell 0.6% in afternoon trading and remains a bit below its all-time high set last week. The Dow Jones Industrial Average was down 342 points, or 0.7%, as of 12:45 p.m. Eastern time, and the Nasdaq composite was 0.3% lower.Treasury yields eased a bit, following a larger initial ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Core Viewpoint - The article highlights three standout companies in the Dow Jones Industrial Average that are considered great long-term investment opportunities due to their strong dividend yields and solid business fundamentals. Group 1: High-Yield Dividend Stocks - Verizon Communications offers a dividend yield of 6.66%, making it an attractive option for investors seeking passive income, especially if interest rates continue to decline [4][5] - Chevron has a dividend yield of 4.55% and has generated nearly $187 billion in revenue over the past four quarters, supporting its dividend payments [6][7] - Merck provides a dividend yield of 3.23% and has a strong pipeline of drugs, ensuring its dividend remains stable despite potential patent losses in the future [9][10] Group 2: Additional Dividend Stocks - Amgen has a dividend yield of 3% and has consistently increased its annual dividend since 2011, with a payout ratio below 50%, indicating strong financial support for its dividends [12][13] - Coca-Cola, with a dividend yield of 2.92%, is recognized for its brand strength and has a history of 63 consecutive years of annual dividend increases, making it a reliable investment [14][15] Group 3: Investment Recommendations - The article suggests that Chevron, Merck, and Coca-Cola stand out as the best investment choices heading into the new year due to their strong fundamentals and dividend performance [16]

Core Insights - Eli Lilly & Co. is recognized for its innovative treatments and strong market presence, particularly in the obesity therapeutics market, which has significantly contributed to its recent success [1][4] - The stock has received upgrades from Daiwa and maintains a Buy rating from Bank of America, indicating strong confidence in the company's future performance [2][6] Stock Performance - As of December 16, 2025, Eli Lilly's stock price was $1,062.71, reflecting a 3.43% increase or $35.20 [5] - The stock has fluctuated between $1,032.55 and $1,065 during the trading day, with a yearly high of $1,111.99 and a low of $623.78 [5] Analyst Ratings and Price Targets - Daiwa upgraded Eli Lilly's stock from Neutral to Buy, reflecting confidence in the company's market position and innovative treatments [6] - Bank of America adjusted its price target from $1,286 to $1,268 while maintaining a Buy rating, indicating a strategic outlook on the stock's potential [2][6] Growth Opportunities - Eli Lilly's leadership in injectable GLP-1s is well recognized, with significant growth opportunities anticipated from the upcoming launch of Orfoglipron, an oral GLP-1 weight-loss pill expected in 2026 [3] - The U.S. rollout and international expansion of Orfoglipron are expected to be major growth drivers for the company [3] Revenue Growth - The company's focus on weight loss drugs has led to double-digit revenue growth, positioning Eli Lilly as a growth stock in the pharmaceutical industry [4][6] - The success of its weight loss drugs has resulted in blockbuster sales, contributing to a share price increase of over 30% this year [4]

Core Viewpoint - EUROAPI's main shareholders, Sanofi and EPIC Bpifrance, have agreed to extend their lock-up period until December 18, 2026, enhancing the stability of EUROAPI's shareholding structure during the execution of its FOCUS-27 plan [1] Business Update - The execution of the FOCUS-27 plan is progressing well, with ongoing improvements in cost efficiency across the organization [1] - EUROAPI anticipates a mid-single digit decrease in Full Year 2025 Net Sales on a comparable basis, a revision from the previously communicated low-single digit decline [5] - The Core EBITDA margin objective for Full Year 2025 remains within the 7% to 9% range due to effective cost reduction measures [5] - A further update will be provided on March 3, 2026, alongside the Full Year 2025 Results [1][5] Company Overview - EUROAPI focuses on reinventing active ingredient solutions to meet global customer and patient needs, with approximately 200 products in its portfolio [2] - The company operates five manufacturing sites in Europe and serves customers in over 80 countries [3] - EUROAPI is listed on Euronext Paris under the ticker EAPI [3]

Core Insights - AstraZeneca and Daiichi Sankyo received FDA approval for Enhertu as a first-line treatment for HER2-positive breast cancer, in combination with Roche's Perjeta [2][7] - The approval is based on the DESTINY-Breast09 study, which showed a significant improvement in progression-free survival [5][7] - AstraZeneca will pay Daiichi Sankyo a $150 million milestone payment following this approval [3][7] Regulatory and Clinical Data - Enhertu was reviewed under the FDA's real-time oncology review program and is already approved in over 85 countries for second-line treatment of HER2-positive breast cancer [3] - The DESTINY-Breast09 study demonstrated a median progression-free survival of 40.7 months for the Enhertu-Perjeta combination, compared to 26.7 months for the standard regimen, reducing the risk of progression by 44% [5][7] Financial Performance - Over the past year, AstraZeneca's shares increased by 36.3%, outperforming the industry average rise of 12.1% [4] - AstraZeneca and Daiichi Sankyo have a collaboration agreement initiated in March 2019, with an expansion in July 2020 to include Datroway [8]

Key Takeaways FOLD touched a 52-week high as shares rally 87.6% in six months, beating the industry, sector and S&P 500.Galafold is the key revenue driver, generating $371.5M in the first nine months of 2025, up 12% Y/Y.Pombiliti Opfolda sales reached $77.5M in the first nine months of 2025, reflecting 61.5% y/y growth.Shares of Amicus Therapeutics (FOLD) touched a 52-week high of $11.14 on Dec. 15. The stock is currently trading at $10.88.Shares of Amicus have surged 87.6% in the past six months compared w ...